In this issue:
Nemolizumab for atopic dermatitis with pruritus
Risankizumab for moderate-tosevere plaque psoriasis
Indirect comparison of ixekizumab 2- vs 4-weekly
Secukinumab for patients failing TNF-α inhibitor therapy
Ixekizumab vs guselkumab for moderate-to-severe plaque psoriasis
New-onset IBD after IL-17 inhibitors
IL-23/-17 biologics effect on subclinical atherosclerosis
Dupilumab for chronic nodular prurigo
Suicidal behaviours in HS treated with TNF-α antagonists
Ixekizumab for patients with pityriasis rubra pilaris
Please login below to download this issue (PDF)